FY2024 Earnings Estimate for CRSP Issued By Zacks Research

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Zacks Research lifted their FY2024 earnings estimates for CRISPR Therapeutics in a report issued on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($5.20) for the year, up from their prior forecast of ($6.13). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.27) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.47) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($5.61) EPS, Q1 2026 earnings at ($1.28) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.25) EPS and FY2026 earnings at ($2.24) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter last year, the company posted ($1.41) EPS.

A number of other research analysts have also recently issued reports on the company. Truist Financial cut their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Stifel Nicolaus reduced their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Trading Up 3.1 %

NASDAQ CRSP opened at $50.84 on Thursday. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10. The company has a 50 day moving average of $48.05 and a 200-day moving average of $51.69. The firm has a market cap of $4.34 billion, a price-to-earnings ratio of -17.96 and a beta of 1.67.

Insider Activity

In related news, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,382 shares of company stock valued at $1,917,679 in the last ninety days. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. raised its stake in CRISPR Therapeutics by 12.7% in the 3rd quarter. Franklin Resources Inc. now owns 7,097 shares of the company’s stock valued at $339,000 after acquiring an additional 800 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics during the third quarter worth approximately $40,000. Sanctuary Advisors LLC raised its holdings in CRISPR Therapeutics by 17.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company’s stock valued at $398,000 after acquiring an additional 1,258 shares in the last quarter. Sunbelt Securities Inc. raised its stake in CRISPR Therapeutics by 11.3% in the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock valued at $139,000 after purchasing an additional 300 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after buying an additional 35,196 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.